Brief: FDA Grants Orphan Drug Designation By NS Pharma To Ns-229 For Treatment Of Eosinophilic Granulomatosis With Polyangiitis
21/04/2025 12:23
April 21 (Reuters) - Nippon Shinyaku Co Ltd 4516.T: NS PHARMA: FDA GRANTS ORPHAN DRUG DESIGNATION TO NS-229 FOR TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS Source text: ID:nPn6cmDLXa Further company coverage: 4516.T
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)